NeoImmuneTech (A950220) Q1 2025 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-I7 as the lead pipeline in both oncology and non-oncology indications.

• No commercial product sales yet; revenue generated from research services during development.

• Multiple ongoing clinical trials in the US and Europe, including collaborations with Merck and Roche.

• Listed on KOSDAQ since 2021 as a technology growth company.

Financial highlights

• Q1 2025 consolidated revenue: $9,111, all from research services.

• Operating loss: $(5,564,406); net loss: $(5,715,924); basic/diluted EPS: $(0.29).

• Cash and cash equivalents at period end: $19,409,042.

• Accumulated deficit: $227,001,988 as of March 31, 2025.

• R&D expenses (consolidated): $3,465,058 in Q1 2025, representing over 38,000% of revenue.

Outlook and guidance

• Continues to pursue licensing-out and direct commercialization strategies for NT-I7.

• Expects revenue growth upon successful out-licensing or FDA approval.

• Ongoing efforts to secure government grants, optimize operations, and improve cash flow.